BioCentury
ARTICLE | Clinical News

ICA-105665: Suspended Phase IIa enrollment

September 20, 2010 7:00 AM UTC

Icagen suspended further enrollment in a single-blind, placebo-controlled, dose-ranging, U.S. Phase IIa trial after reporting that 1 patient experienced an undisclosed serious adverse event after rece...